BioRestorative Therapies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2009
Net Income	-6.96	-10.42	-13.22	-44.3	-11.27	-14.65	Upgrade
Depreciation & Amortization	0.27	0.26	0.28	0.21	0.15	0.23	Upgrade
Share-Based Compensation	6.47	7.78	12.61	23.11	0.69	1.66	Upgrade
Other Operating Activities	-6.18	-4.05	-5.58	17.66	8.46	5.84	Upgrade
Operating Cash Flow	-6.4	-6.43	-5.91	-3.33	-1.96	-6.92	Upgrade
Capital Expenditures	-0.11	-0.17	-0.27	-0.03	0	-0.04	Upgrade
Change in Investments	-4.07	3.42	-12.96	0	0	0	Upgrade
Other Investing Activities	-	-	-0.18	-	-	-	Upgrade
Investing Cash Flow	-4.18	3.25	-13.4	-0.03	0	-0.04	Upgrade
Share Issuance / Repurchase	2.35	2.35	0	21.07	0.01	1.66	Upgrade
Debt Issued / Paid	0	0	0	0.25	5.52	5.18	Upgrade
Other Financing Activities	7.52	-	-	-	-0.5	-	Upgrade
Financing Cash Flow	9.87	2.35	0	21.32	5.03	6.84	Upgrade
Net Cash Flow	-0.72	-0.83	-19.31	17.96	3.06	-0.12	Upgrade
Free Cash Flow	-6.51	-6.6	-6.18	-3.36	-1.96	-6.95	Upgrade
Free Cash Flow Margin	-4354.70%	-4527.61%	-5157.20%	-7305.58%	-2550.99%	-5349.51%	Upgrade
Free Cash Flow Per Share	-0.98	-1.56	-1.71	-2.83	-4.98	-1248.69	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).